Ureteral stents are commonly used internal drainage devices after minimally invasive urological surgeries such as ureteroscopic lithotripsy and percutaneous nephrolithotomy. Their core functions are to relieve ureteral obstruction, facilitate urinary tract repair and stone passage, and they have become an essential auxiliary measure for the treatment of urinary calculi, ureteral stricture and othe
Conditions
Interventions
Group of patients with indwelling ureteral stents:None
Sponsors
The first hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years old, regardless of gender, with clear consciousness and normal communication ability. 2. Patients who underwent ureteroscopic lithotripsy (URS) or percutaneous nephrolithotomy (PCNL) for urinary calculi, ureteral stricture and other diseases and had indwelling ureteral stents after surgery. 3. Patients who voluntarily participated in the study after surgery, were able to complete the scale independently or with assistance from researchers, and signed the informed consent form. 4. Patients with a planned follow-up duration of no less than 28 days during stent indwelling, and who could cooperate with scale assessments at multiple time points (1, 3, 7, 14 and 28 days after surgery).
Exclusion criteria
Exclusion criteria: 1. Patients with severe cognitive impairment, mental disorders or language dysfunction who are unable to understand scale items or complete follow-up. 2. Patients complicated with severe underlying diseases such as cardiac, hepatic, renal and coagulation disorders that may interfere with the evaluation of complications. 3. Patients with preoperative persistent hematuria, recurrent urinary tract infection, chronic pain syndrome and other conditions that may affect the judgment of stent-related complications. 4. Pregnant or lactating women, as well as patients with an expected stent indwelling duration of less than 28 days or scheduled early stent removal. 5. Patients who strongly refuse scale assessments (e.g., pain faces scale, hematuria color chart) or decline to provide information within the scope of privacy protection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Development and Validation of a Simple Scale for Symptoms Related to Ureteral Stent Tubes; | — |
Countries
China
Contacts
Public ContactZhao Hua
The first hospital of Shanxi Medical University
Outcome results
None listed